SCHEMBL1935138

SCHEMBL1935138

Cc1ccc(C(=O)N(c2ccccn2)C2CC2)cc1-c1cnc2oc(-c3ccc(F)cc3)c(C(=O)O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
CYP2C8 P10632 6/20 0.43
CYP3A4 P08684 5/20 0.43
KCNH2 Q12809 3/20 0.43
NR1I2 O75469 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.38
NPC1 O15118 1/20 0.37
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ABL1 P00519 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936381 0.92 CYP2C8 (0.53) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL2434818 0.92 ALDH1A1 (0.45) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL1937242 0.91 ALDH1A1 (0.47) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL1936895 0.84 CYP2C8 (0.54) CYP2C8CYP3A4KCNH2NR1I2ABL1
SCHEMBL2433685 0.84 ALDH1A1 (0.45) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL2437777 0.84 ALDH1A1 (0.45) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL1918435 0.81 CYP2C8 (0.65) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL1936239 0.78 CYP2C8 (0.54) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL2994579 0.78 CYP2C8 (0.70) CYP2C8CYP3A4KCNH2NR1I2ABL1
SCHEMBL1936918 0.75 CYP2C8 (0.52) ALDH1A1CYP2C8CYP3A4KCNH2NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2545050-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-01-16 EP disclosed
WO-2011112186-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 WO disclosed
EP-2331502-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2011-06-15 EP disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 WO disclosed